Talking Medicines targets growing demand for GLP-1 patient intelligence

Tern plc

Talking Medicines is using consumer conversations around GLP-1 weight-loss plateaus to show how behavioural data can help life sciences companies better understand patients, treatment expectations and communication needs.

The company’s analysis found that many consumers do not automatically see a weight-loss plateau as treatment failure. Instead, they discuss practical responses such as changing exercise habits, improving hydration and considering dose adjustments. These conversations also show patients actively comparing experiences and seeking advice from others.

Patient behaviour can affect adherence, expectations and the way treatment is perceived over time. For pharmaceutical companies, understanding these shifts can help improve patient education, support programmes and communication strategies.

Talking Medicines describes this trend as informed consumerisation. Patients are becoming more active in treatment decisions and are using online information and peer experiences to shape their views. That creates demand for tools that can capture and interpret what patients are saying outside traditional clinical settings.

The company’s analysis also found that attitudes can change as treatment progresses. Early focus on rapid weight loss may move towards maintenance, tolerance and longer-term lifestyle goals. Consumers also discuss frustration, motivation and uncertainty, showing that emotional responses can influence how they view treatment.

Dose stability, side effects and medication tolerance become more important as treatment continues. These factors can affect whether patients remain engaged and how they respond to medical or commercial messaging.

Talking Medicines’ DrugVoice platform converts unstructured healthcare conversations into behavioural intelligence. The aim is to help life sciences companies understand not only what patients are saying, but why attitudes and behaviours may be changing.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority highlights security risks as AI begins controlling physical machines

Device Authority examines the security risks of AI-controlled machinery and the role of device identity, authentication and access controls in protecting physical equipment.

Talking Medicines targets better pharmaceutical launch results through message analysis

Talking Medicines' Message Resonance Score measures doctors' understanding of pharmaceutical messaging to help companies improve launch strategies.

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

Search